IGC Pharma, Inc. — Capital/Financing Update 2026

Jun 8, 2026

xml version='1.0' encoding='ASCII'? Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 Field: Set; Name: xdx; ID: xdx_03A_IGC_igcpharma.com_20260605 Field: Set; Name: xdx; ID: xdx_04C_20260605_20260605 Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001326205 Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Field: Rule-Page

Field: /Rule-Page

FORM 8-K

Field: Rule-Page

Field: /Rule-Page

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 5, 2026

IGC PHARMA, INC.

(Exact name of registrant as specified in charter)

Maryland	001-32830	20-2760393
(State
or other jurisdiction of incorporation)	(Commission
File Number)	(I.R.S.
Employer Identification No.)

10224 Falls Road , Potomac , Maryland 20854

(Address of principal executive offices) (Zip Code)

(301) 983-0998

(Registrant’s telephone number, including area code)

Field: Rule-Page

Field: /Rule-Page

(Former Name or Former Address, if Changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title
of each class | Trading
Symbol(s) | Name
of each exchange on which registered |
| --- | --- | --- |
| Common
Stock, $.0001 par value | IGC | NYSE
American |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☐ .

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 1.01 Entry into a Material Definitive Agreement

Extension of Master Loan and Security Agreement

On June 5, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) entered into an amendment to extend its existing Master Loan and Security Agreement together with the General Banking Facility Letter (collectively, the “Loan Agreement”) with O-Bank Co., Ltd., a banking corporation incorporated under the laws of Taiwan, as lender (the “Lender”).

The Loan Agreement continues the facility arrangement previously set forth in the General Banking Facility Letter dated June 24, 2025. The facility provides for a maximum aggregate limit of $12,000,000. The material terms of the facility remain substantially unchanged from the 2025 facility letter, except that the facility fee has increased from $48,000 to $60,000.

The foregoing summary of the Loan Agreement is qualified in its entirety by reference to the full text of the Loan Agreement, a copy of which is filed hereto as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
10.1*	2026 O-Bank General Banking
Facility Letter.
10.2*	2025 O-Bank
General Banking Facility Letter (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for
the quarter ended June 30, 2025, filed with the Securities and Exchange Commission on August 14, 2025).
104	Cover Page Interactive Data
File (formatted as Inline XBRL).

• Certain schedules or similar attachments to this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K.

The registrant hereby agrees to furnish supplementally to the Securities and Exchange Commission upon request a copy of any omitted schedule or attachment to this exhibit.

Field: Page; Sequence: 2; Options: NewSection; Value: 1

Field: Sequence; Type: Arabic; Name: PageNo 1 Field: /Sequence

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Dated:
June 8, 2026
By:	/s/ Ram
Mukunda
	Name:	Ram Mukunda
	Title:	CEO

Field: Page; Sequence: 3; Options: Last

Field: Sequence; Type: Arabic; Name: PageNo 2 Field: /Sequence

Field: /Page

Field: Set; Name: xdx; ID: xdx_08B_extensions eJxFjd0KwjAMhZ9g7xB6LdpNHLJLh4o4ZQwRb4vLpNg1I61/j+RbWjfEEAjJOV+OECOxppU2yHBaVAUcsO2M8ggVNshozxgc+WabQZgVXrTzrKzv1x9YmpuDdDxT4da77tphnYFMJ3I+SVKQSRZPodyJ6KvnZBtdo/VaGVC2hpKpY41e8Wv4cFBPstS++pQjstNkM4jHcpDfkMg4gT3d1YP46qAochGN+orEmunWBdfy6dF+SVgabEOcG+h/Rx9QEEjL